PMID- 35574331
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220716
IS  - 2234-943X (Print)
IS  - 2234-943X (Electronic)
IS  - 2234-943X (Linking)
VI  - 12
DP  - 2022
TI  - Short-Term Outcomes and Clinical Efficacy of Stereotactic Body Radiation Therapy 
      (SBRT) for Oligometastases of Prostate Cancer in China.
PG  - 879310
LID - 10.3389/fonc.2022.879310 [doi]
LID - 879310
AB  - OBJECTIVE: To assess the efficacy and safety of stereotactic body radiation 
      therapy (SBRT) in managing oligometastases of prostate cancer. Moreover, it is 
      the largest-to-date study in China to report the safety and efficacy of SBRT by 
      CyberKnife for oligometastases of prostate cancer. METHODS: In this retrospective 
      study, 75 patients with 108 oligometastases were treated by SBRT from May 2012 to 
      February 2021. Among these patients, 43 patients were treated with the intention 
      to control all known metastatic lesions and 32 were treated for palliative care. 
      Patients received regular follow-up evaluations every 3 months. Efficacy was 
      assessed based on local control (LC) rates, biochemical progression-free survival 
      (bPFS), progression-free survival (PFS), and overall survival (OS). Safety was 
      assessed based on clinical adverse events. RESULTS: Median follow-up time was 
      23.2 months (1.2-106.9 months). The complete response (CR), partial response 
      (PR), stable disease (SD), and progressive disease (PD) rates were 63.0%, 10.2%, 
      21.3% and 5.6%, respectively. The 6-month, 1-, and 2-year LC rates were 100%, 
      97.5%, and 96.0% respectively while the 6-month, 1-, and 2-year bPFS rates were 
      74.6%, 53.3%, and 47.9%, respectively. Additionally, 6-month, 1-, and 2-year PFS 
      rates were 77.5%, 50.8%, and 47.2%, respectively. The 6-month, 1-, and 2-year OS 
      rates were 97.0%, 88.8%, and 87.0%, respectively. For the 15 metastatic 
      castration-resistant prostate cancer (mCRPC) patients with 23 lesions, the 2-year 
      LC rates were 93.8%, while for 60 metastatic hormone-sensitive prostate cancer 
      (mHSPC) patients with 85 lesions, the 2-year LC rates were 96.7%. No predictors 
      of LC were found after univariate analysis. In those not on androgen deprivation 
      therapy (ADT; n = 27), the 2-year freedom from ADT was 44.0%. All of the 24 
      patients with oligmetastase-induced complications experienced varying degrees of 
      alleviation after SBRT. The treatment was well tolerated. No grade 3 or higher 
      toxicity was observed. CONCLUSION: SBRT is a safe and effective treatment 
      modality in the management of oligometastases of mHSPC and mCRPC with high LC 
      rates and acceptable toxicity. SBRT could provide a treatment choice for mCRPC, 
      as well as an alternative to delay the start of ADT for mHSPC.
CI  - Copyright (c) 2022 Xu, Zhao, Ju, Shen, Qu, Ye, Wang, Yu, Gao and Zhang.
FAU - Xu, Chenyang
AU  - Xu C
AD  - Department of Urology, Huashan Hospital, Fudan University, Shanghai, China.
FAU - Zhao, Xianzhi
AU  - Zhao X
AD  - Department of Radiation Oncology, Shanghai Changhai Hospital, The Navy Medical 
      University, Shanghai, China.
FAU - Ju, Xiaoping
AU  - Ju X
AD  - Department of Radiation Oncology, Shanghai Changhai Hospital, The Navy Medical 
      University, Shanghai, China.
FAU - Shen, Yuxin
AU  - Shen Y
AD  - Department of Radiation Oncology, Shanghai Changhai Hospital, The Navy Medical 
      University, Shanghai, China.
FAU - Qu, Min
AU  - Qu M
AD  - Department of Urology, Shanghai Changhai Hospital, The Navy Medical University, 
      Shanghai, China.
FAU - Ye, Yusheng
AU  - Ye Y
AD  - Department of Radiation Oncology, Shanghai Changhai Hospital, The Navy Medical 
      University, Shanghai, China.
FAU - Wang, Xiaoyan
AU  - Wang X
AD  - Department of Radiation Oncology, Shanghai Changhai Hospital, The Navy Medical 
      University, Shanghai, China.
FAU - Yu, Chunshan
AU  - Yu C
AD  - Department of Radiation Oncology, Shanghai Changhai Hospital, The Navy Medical 
      University, Shanghai, China.
FAU - Gao, Xu
AU  - Gao X
AD  - Department of Urology, Shanghai Changhai Hospital, The Navy Medical University, 
      Shanghai, China.
FAU - Zhang, Huojun
AU  - Zhang H
AD  - Department of Radiation Oncology, Shanghai Changhai Hospital, The Navy Medical 
      University, Shanghai, China.
LA  - eng
PT  - Journal Article
DEP - 20220428
PL  - Switzerland
TA  - Front Oncol
JT  - Frontiers in oncology
JID - 101568867
PMC - PMC9095840
OTO - NOTNLM
OT  - efficacy
OT  - metastatic castration-resistant prostate cancer (mCRPC)
OT  - metastatic hormone-sensitive prostate cancer (mHSPC)
OT  - oligometastases
OT  - stereotactic body radiotherapy (SBRT)
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/05/17 06:00
MHDA- 2022/05/17 06:01
PMCR- 2022/01/01
CRDT- 2022/05/16 04:42
PHST- 2022/02/19 00:00 [received]
PHST- 2022/03/28 00:00 [accepted]
PHST- 2022/05/16 04:42 [entrez]
PHST- 2022/05/17 06:00 [pubmed]
PHST- 2022/05/17 06:01 [medline]
PHST- 2022/01/01 00:00 [pmc-release]
AID - 10.3389/fonc.2022.879310 [doi]
PST - epublish
SO  - Front Oncol. 2022 Apr 28;12:879310. doi: 10.3389/fonc.2022.879310. eCollection 
      2022.